Search

everythinglearnresearchcommunity

for

Search:↓

Most COVID-19 survivors developed post-acute symptoms, especially if they had been in the ICU, but the severity of initial infection didn't predict these symptoms.

New treatments for COVID-19 show promise, but more effective antiviral drugs are needed.

Long COVID causes lasting symptoms and needs vaccines for prevention and a team approach for treatment.

Most COVID-19 patients had lingering symptoms 60 days after leaving the hospital.

Many hospitalized COVID-19 patients still have symptoms like fatigue and hair loss up to a year later, especially older, lower-income individuals with other health issues.

One-third of COVID-19 patients had long-term symptoms like hair loss and fatigue, with women, older individuals, blood group B, smokers, and those with more virus exposure at higher risk.

Cepharanthine shows promise as a COVID-19 treatment.

Antiandrogens don't help with COVID-19 and aren't recommended.

Different ACE2 gene versions may affect COVID-19 impact based on age and suggest some hair loss drugs could be potential treatments.

Antiandrogens may help prevent or treat COVID-19 by blocking virus entry into cells.

Standardized definitions and better methods are needed to accurately estimate long COVID-19 prevalence.

Most hospitalized COVID-19 survivors in the study experienced long-term symptoms, affecting their daily life and mental functions.

CTCL patients can safely continue treatment during COVID-19 with proper safety measures.

Some COVID-19 pneumonia patients in Veracruz, Mexico, had skin issues, with reversible hair loss linked to disease severity.

Low testosterone and SHBG levels are linked to higher COVID-19 death rates.

Kidney transplant patients who had COVID-19 experienced a significant drop in their quality of life due to long-lasting symptoms.

Older, obese people with many COVID-19 symptoms are more likely to suffer from severe long-term COVID-19 effects.

Anemia increases the risk of hair loss in post-COVID-19 survivors.

BCG site reactions after COVID-19 mRNA vaccination are mild, temporary, and likely under-reported.

A COVID-19 patient had severe and long-lasting skin issues and unusual hair loss.

Women are more likely to have long-term post-COVID symptoms than men.

Certain skin rashes can indicate COVID-19 severity, with chilblains-like rashes linked to milder cases and livedoid patterns to more severe cases.

Some drugs may help treat both COVID-19 and radiation injury.

Some nutraceuticals may help in COVID-19 prevention and treatment, but more research is needed.

Men are more at risk for severe COVID-19 due to biological differences, suggesting the need for targeted treatments.

Sex hormones may influence COVID-19 severity, with males at higher risk, and certain hormone therapies could potentially treat the virus.

Psoriasis treatments don't raise severe COVID-19 risk, except for acitretin.

Many hospitalized children with COVID-19 had skin, mouth, or nail changes, with skin rashes being common.

Certain skin symptoms in COVID-19 patients may indicate a more severe illness.

New-onset fibromyalgia after COVID-19 is poorly understood and needs more research.